Search Images Maps Play YouTube News Gmail Drive More »
Advanced Patent Search | Web History | Sign in

Patents

Oxygen-independent methods, systems and devices for the enzymatic colorimetric assay and detection of biochemical analytes. Two systems are described, both of which produce less than one equivalent of dye per equivalent of substrate, maintaining dye concentrations in the range where Beer's law predicts a linear color-concentration relationship. One system produces an analog color signal from an analog analyte input, the other system produces a digital color signal from an analog analyte input.

InventorsJohn L. Palmer, James B. Johnston, Marsha W. Timmerman
Original AssigneeEnzymatics, Inc.
Primary Examiner: Toni R. Scheiner
Current U.S. Classification435/25; 435/4; 435/26; 435/174; 435/175; 435/287.1; 435/309.1; 435/805; 435/810
International Classification: C12Q 126; C12M 140

View patent at USPTO
Search USPTO Assignment Database

Citations

Cited PatentFiling dateIssue dateOriginal AssigneeTitle
US3964871Dec 18, 1974Jun 22, 1976Becton, Dickinson and CompanyMethod and device for detecting glucose
US4556634Jun 22, 1983Dec 3, 1985Toyo Jozo Kabushiki KaishaHigh sensitivity assay method
US4629697Dec 23, 1983Dec 16, 1986Merck Patent Gesellschaft mit beschrankter HaftungTest system and procedure for the determination of NAD (P) H
US4761381Feb 26, 1987Aug 2, 1988Miles Inc.Volume metering capillary gap device for applying a liquid sample onto a reactive surface

Referenced by

Citing PatentFiling dateIssue dateOriginal AssigneeTitle
US5278079Sep 2, 1992Jan 11, 1994Enzymatics, Inc.Sealing device and method for inhibition of flow in capillary measuring devices
US5439813Jun 3, 1994Aug 8, 1995E. I. Du Pont de Nemours and CompanyProduction of glyoxylic acid with glycolate oxidase and catalase immobilized on oxirane acrylic beads
US5510245Jan 18, 1994Apr 23, 1996Bayer CorporationComposition and method of assaying for ketone bodies
US5518891Aug 25, 1993May 21, 1996Actimed Laboratories, Inc.Dye forming composition and detection of hydrogen peroxide therewith
US5523214May 9, 1994Jun 4, 1996Biotest AktiengesellschaftMethod of visually demonstrating the presence of microorganisms, identifying them, and testing them for sensitivity to antibiotics with redox indicators
US5550028Jun 7, 1995Aug 27, 1996Dade International Inc.Tetrahydroxyquinone as an activator component for activated partial thromboplastin time test of blood coagulation
US5583006May 4, 1995Dec 10, 1996Boehringer Mannheim CorporationStabilizing tetrazolium salts in a reagent
US5702955Oct 6, 1995Dec 30, 1997Bayer CorporationAscorbate resistant detection of hydrogen peroxide
US5837546Jun 7, 1996Nov 17, 1998Metrika, Inc.Electronic assay device and method
US5968746Nov 26, 1997Oct 19, 1999Method and apparatus for preserving human saliva for testing
US6120676Jun 4, 1999Sep 19, 2000Therasense, Inc.Method of using a small volume in vitro analyte sensor
US6143164Dec 16, 1998Nov 7, 2000E. Heller & CompanySmall volume in vitro analyte sensor
US6251260Aug 24, 1998Jun 26, 2001TheraSense, Inc.Potentiometric sensors for analytic determination
US6291178Aug 30, 1999Sep 18, 2001Method and apparatus for preserving human saliva for testing
US6299757Oct 6, 1999Oct 9, 2001TheraSense, Inc.Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US6338790Apr 21, 1999Jan 15, 2002TheraSense, Inc.Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US6461496Oct 27, 1999Oct 8, 2002TheraSense, Inc.Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US6534300Aug 10, 2000Mar 18, 2003Genzyme Glycobiology Research Institute, Inc.Methods for producing highly phosphorylated lysosomal hydrolases
US6537785Aug 10, 2000Mar 25, 2003Genzyme Glycobiology Research Institute, Inc.Methods of treating lysosomal storage diseases
US6551494Apr 6, 2000Apr 22, 2003Therasense, Inc.Small volume in vitro analyte sensor
US6576101Oct 6, 1999Jun 10, 2003TheraSense, Inc.Small volume in vitro analyte sensor
US6591125Jun 27, 2000Jul 8, 2003TheraSense, Inc.Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US6592745May 17, 2000Jul 15, 2003TheraSense, Inc.Method of using a small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US6616819Nov 4, 1999Sep 9, 2003TheraSense, Inc.Small volume in vitro analyte sensor and methods
US6618934Jun 15, 2000Sep 16, 2003TheraSense, Inc.Method of manufacturing small volume in vitro analyte sensor
US6654625Jun 16, 2000Nov 25, 2003TheraSense, Inc.Mass transport limited in vivo analyte sensor
US6656697Feb 25, 2000Dec 2, 2003Lifescan, Inc.Diagnostics based on tetrazolium compounds
US6670165Nov 9, 2001Dec 30, 2003Genzyme Glycobiology Research Institute, Inc.Methods for producing highly phosphorylated lysosomal hydrolases
US6749740Dec 28, 2001Jun 15, 2004TheraSense, Inc.Small volume in vitro analyte sensor and methods
US6800472Dec 21, 2001Oct 5, 2004Genzyme Glycobiology Research Institute, Inc.Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester
US6828135Nov 29, 2002Dec 7, 2004Genzyme Glycobiology Research Institute, Inc.Phosphodiester
US6861242Jul 2, 2001Mar 1, 2005Genzyme Glycobiology Research Institute, Inc.Methods for producing highly phosphorylated lysosomal hydrolases
US6905856Dec 21, 2001Jun 14, 2005Genzyme Glycobiology Research Institute, Inc.Soluble GlcNAc phosphotransferase
US6942518Dec 28, 2001Sep 13, 2005TheraSense, Inc.Small volume in vitro analyte sensor and methods
US6975893Nov 25, 2003Dec 13, 2005TheraSense, Inc.Mass transport limited in vivo analyte sensor
US7005273May 14, 2002Feb 28, 2006TheraSense, Inc.Method for the determination of glycated hemoglobin
US7011954Sep 15, 2003Mar 14, 2006Lifescan, Inc.Diagnostics based on tetrazolium compounds
US7041468Mar 29, 2002May 9, 2006TheraSense, Inc.Blood glucose tracking apparatus and methods
US7058437Apr 17, 2003Jun 6, 2006TheraSense, Inc.Methods of determining concentration of glucose
US7067127Sep 9, 2003Jun 27, 2006Genzyme Glycobiology Research Institute Inc.GIcNAc phosphotransferase of the lysosomal targeting pathway
US7102011Dec 18, 2001Sep 5, 2006Methods and compositions for the visualization of cellular organelles using tetrazolium salts
US7135322Jul 29, 2004Nov 14, 2006Novazyme Pharmaceuticals, Inc.Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
US7144709Nov 16, 2004Dec 5, 2006LifeScan, Inc.Diagnostics based on tetrazolium compounds
US7150995Jan 16, 2004Dec 19, 2006Metrika, Inc.Methods and systems for point of care bodily fluid analysis
US7225535Sep 12, 2003Jun 5, 2007Abbott Diabetes Care, Inc.Method of manufacturing electrochemical sensors
US7371366Aug 9, 2005May 13, 2008Genzyme CorporationGlcNAc phosphotransferase of the lysosomal targeting pathway
US7550069Sep 12, 2003Jun 23, 2009Abbott Diabetes Care Inc.Small volume in vitro analyte sensor
US7563350Sep 15, 2003Jul 21, 2009Abbott Diabetes Care Inc.Small volume in vitro analyte sensor
US7587287Apr 4, 2003Sep 8, 2009Abbott Diabetes Care Inc.Method and system for transferring analyte test data
US7620438Mar 31, 2006Nov 17, 2009Abbott Diabetes Care Inc.Method and system for powering an electronic device
US7635597Apr 19, 2004Dec 22, 2009Bayer HealthCare LLCDry reagent particle assay and device having multiple test zones and method therefor
US7766829Nov 4, 2005Aug 3, 2010Abbott Diabetes Care Inc.Method and system for providing basal profile modification in analyte monitoring and management systems
US7799578May 29, 2007Sep 21, 2010Roche Diagnostics GmbHCapillary active test element having an intermediate layer situated between the support and the covering
US7811231Dec 26, 2003Oct 12, 2010Abbott Diabetes Care Inc.Continuous glucose monitoring system and methods of use
US7811689Jun 26, 2007Oct 12, 2010Abbott Diabetes Care Inc.Biological fuel cell and methods
US7860544Mar 7, 2007Dec 28, 2010Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US7869853Aug 6, 2010Jan 11, 2011Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US7885699Aug 6, 2010Feb 8, 2011Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US7906009Jul 30, 2008Mar 15, 2011Abbott Diabetes Care Inc.Small volume in vitro analyte sensor
US7909984Feb 7, 2008Mar 22, 2011Abbott Diabetes Care Inc.Small volume in vitro analyte sensor
US7920907Jun 7, 2007Apr 5, 2011Abbott Diabetes Care Inc.Analyte monitoring system and method
US7928850May 8, 2008Apr 19, 2011Abbott Diabetes Care Inc.Analyte monitoring system and methods
US7976778Jun 22, 2005Jul 12, 2011Abbott Diabetes Care Inc.Blood glucose tracking apparatus
US7988845Jan 28, 2008Aug 2, 2011Abbott Diabetes Care Inc.Integrated lancing and measurement device and analyte measuring methods
US7998624Sep 7, 2010Aug 16, 2011Abbott Diabetes Care Inc.Biological fuel cell and methods
US7998625Nov 11, 2010Aug 16, 2011Abbott Diabetes Care Inc.Biological fuel cell and methods
US8066639Jun 4, 2004Nov 29, 2011Abbott Diabetes Care Inc.Glucose measuring device for use in personal area network
US8066858Oct 31, 2007Nov 29, 2011Abbott Diabetes Care Inc.Analyte sensor with insertion monitor, and methods
US8067188Apr 16, 2010Nov 29, 2011N2ITIVE1 InnovationsAnalyte detection
US8083924Sep 29, 2009Dec 27, 2011Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8083928Sep 29, 2009Dec 27, 2011Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8083929Sep 29, 2009Dec 27, 2011Abbott Diabetes Care Inc.Small volume in vitro sensor and methods of making
US8087162Sep 29, 2009Jan 3, 2012Abbott Diabetes Care Inc.Methods of making small volume in vitro analyte sensors
US8091220Oct 31, 2007Jan 10, 2012Abbott Diabetes Care Inc.Methods of making small volume in vitro analyte sensors
US8103456Jan 29, 2009Jan 24, 2012Abbott Diabetes Care Inc.Method and device for early signal attenuation detection using blood glucose measurements
US8105476Jul 30, 2007Jan 31, 2012Abbott Diabetes Care Inc.Integrated lancing and measurement device
US8112240Apr 29, 2005Feb 7, 2012Abbott Diabetes Care Inc.Method and apparatus for providing leak detection in data monitoring and management systems
US8114270Feb 7, 2008Feb 14, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor
US8114271Sep 29, 2009Feb 14, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor
US8118992Sep 29, 2009Feb 21, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor
US8118993Sep 29, 2009Feb 21, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8123686Mar 1, 2007Feb 28, 2012Abbott Diabetes Care Inc.Method and apparatus for providing rolling data in communication systems
US8123929Sep 29, 2009Feb 28, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor
US8142642Jul 30, 2008Mar 27, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor
US8142643Sep 29, 2009Mar 27, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor
US8149117Aug 29, 2009Apr 3, 2012Abbott Diabetes Care Inc.Analyte monitoring system and methods
US8153063Sep 29, 2009Apr 10, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8162829Mar 30, 2009Apr 24, 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8163164Sep 29, 2009Apr 24, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8175673Nov 9, 2009May 8, 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8177716Dec 21, 2009May 15, 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8182670Sep 29, 2009May 22, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8182671Sep 29, 2009May 22, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8186044Apr 13, 2007May 29, 2012Abbott Diabetes Care Inc.Method of manufacturing small volume in vitro analyte sensors
US8187183Oct 11, 2010May 29, 2012Abbott Diabetes Care Inc.Continuous glucose monitoring system and methods of use
US8187895Sep 29, 2009May 29, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8192611Sep 29, 2009Jun 5, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8206563Dec 6, 2005Jun 26, 2012Abbott Diabetes Care Inc.Device for the determination of glycated hemoglobin
US8211363Sep 29, 2009Jul 3, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8221685Sep 29, 2009Jul 17, 2012Abbott Diabetes Care Inc.Small volume in vitro sensor and methods of making
US8224413Oct 10, 2008Jul 17, 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8226555Mar 18, 2009Jul 24, 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8226557Dec 28, 2009Jul 24, 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8226558Sep 27, 2010Jul 24, 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8226815Sep 29, 2009Jul 24, 2012Abbott Diabetes Care Inc.Small volume in vitro sensor and methods of making
US8226891Mar 31, 2006Jul 24, 2012Abbott Diabetes Care Inc.Analyte monitoring devices and methods therefor
US8231532Apr 30, 2007Jul 31, 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8235896Dec 21, 2009Aug 7, 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8236242Feb 12, 2010Aug 7, 2012Abbott Diabetes Care Inc.Blood glucose tracking apparatus and methods
US8241797Nov 11, 2010Aug 14, 2012Abbott Diabetes Care Inc.Biological fuel cell and methods

Claims

1. A colorimetric assay system which is designed to measure the presence or concentration of a biochemical analyte in a sample by a color change which is indicative of the presence or concentration of the analyte, wherein the system comprises,

(a) an oxidase enzyme capable of oxidizing the analyte by removing electrons from the analyte without involving oxygen in the reaction, thereby yielding a reduced enzyme,
(b) a non-chromogenic electron acceptor which is oxygen, having a half cell reduction potential greater than that of the reduced enzyme, wherein the electron acceptor is capable of accepting electrons from the reduced enzyme in a functionally irreversible manner, and
(c) a chromogen which is capable of accepting electrons from the reduced enzyme and changing color in a visible range upon reduction, wherein the change of color is less than one equivalent of color per equivalent of analyte oxidized and is indicative of the presence or the concentration of the analyte to be determined.

2. The colorimetric assay system of claim 1 wherein the electron acceptor is capable of directly accepting the electrons from the reduced enzyme in a functionally irreversible manner.

3. The colorimetric assay system of claim 1 wherein the analyte is cholesterol and the enzyme is cholesterol oxidase.

4. The colorimetric assay system of claim 3 wherein the chromogen is Azure B.

5. A colorimetric assay system which is designed to measure the presence or concentration of a biochemical analyte by a color change which is determinative of the presence of concentration of the analyte, wherein the system comprises:

(a) an oxidase enzyme capable of electron transferase activity with the analyte and capable of oxidizing the analyte by removing electrons from the analyte without involving oxygen in the reaction, thereby yielding a reduced enzyme,
(b) a chromogen which is capable of accepting electrons derived from the reduced enzyme and is capable of changing color in a visible range upon reduction, the color change of the reduced chromogen being detectable and determinative of the presence or concentration of the analyte to be determined, and
(c) a non-chromogenic electron acceptor which is not oxygen having a half cell potential greater than the reduced enzyme, which electron acceptor is capable of accepting electrons derived from the reduced enzyme in a functionally irreversible manner, and advantageously competes over any oxygen present to oxidize the reduced enzyme, and
(d) an electron transfer agent which promotes the transfer of electrons from the reduced enzyme to the electron acceptor, the chromogen, or both.

6. The colorimetric assay system of claim 5 wherein the electron transfer agent is selected from the group consisting of flavins, phenazines, phenothiazines, pheoxazines, indophenols, substituted 1,4-benzoquinones and indamins.

7. The colorimetric assay system of claim 6 wherein the electron transfer agent is a flavin selected from the group consisting of riboflavin, alloxazine and lumichrome.

8. The colorimetric assay system of claim 6 in which the electron transfer agent is a phenothiazine selected from the group consisting of phenothiazine radical cation, thionine, azure A, azure B, azure C, methylene blue, methylene green and toluidine blue.

9. The colorimetric assay system of claim 6 wherein the electron transfer agent is a phenazine selected from the group consisting of phenazine, phenazine methosulfate, phenazine ethosulfate, and safranine.

10. The colorimetric assay system of claim 6 in which the electron transfer agent is a phenothiazine selected from the group consisting of basic blue 3 and brilliant cresyl blue.

11. The colorimetric assay system of claim 6 in which the electron transfer agent is a substituted 1,4-benzoquinone selected from the group consisting of TFBQ, MMBQ, HMBQ, HMMBQ, DMBQ, DMMBQ and CCBQ.

12. The colorimetric assay system of claim 6 in which the electron transfer agent is an indamin selected from the group consisting of Bindschedler's green and phenylene blue.

13. The colorimetric assay system of claim 5 in which the enzyme is cholesterol oxidase and the analyte is cholesterol.

14. The colorimetric assay system of claim 7 in which the electron transfer agent is DCIP.

15. The colorimetric assay system of claim 14 in which the enzyme is choline oxidase and the analyte is choline.

16. The colorimetric assay system of claim 5 in which the electron acceptor competes with the chromogen for electrons from the enzyme, either retarding reduction of the chromogen and thereby causing the color change to be gradual, or preventing reduction of the chromogen until the non-reduced electron acceptor is depleted and an abrupt color change occurs, the intensity of the gradual color change being linearly proportional to the concentration of the analyte, the occurrence of the abrupt color change being determinative of the presence or absence of the analyte below or above a concentration to be determined.

17. The colorimetric assay system of claim 5 wherein the electron transfer agent is phenothiazine, the chromogen is INT and the electron acceptor is ferric chelate.

18. The colorimetric assay system of claim 5 wherein the electron transfer agent is PMS, the chromogen is MTT and the electron acceptor is ferricyanide.

19. The colorimetric assay system of claim 18 in which the enzyme is alcohol oxidase and the analyte is alcohol.

20. The colorimetric assay system of claim 5 wherein the analyte is cholesterol, the enzyme is cholesterol oxidase, the electron transfer agent is selected from the group consisting of phenothiazine radical, phenoxazine, PMS and a substituted 1,4-benzoquinone, the electron acceptor is selected from the group consisting of K.sub.2 IrCl.sub.6, ferric chelates, ferricyanide, and NaIO.sub.4 and the chromogen is a tetrazolium salt compatible with the electron acceptor, and wherein the assay system is analog to digital.

21. The colorimetric assay system of claim 20 wherein the substituted 1,4-benzoquinone electron transfer agent is selected from the group consisting of TFBQ, MMBQ, DMMBQ and CCBQ.

22. The colorimetric assay system of claim 5 wherein the analyte is cholesterol, the enzyme is cholesterol oxidase, the electron transfer agent is selected from the group consisting of phenothiazine radical cation, phenoxazine, phenazine methosulfate and a substituted 1,4-benzoquinone, the electron acceptor is tartrazine, and the chromogen is a tetrazolium salt compatible with the electron acceptor, and wherein the assay system is analog to analog.

23. The colorimetric assay system of claim 5 in which the oxidase is selected from the group consisting of an oxidase requiring a flavin coenzyme and an oxidase containing a pteridine coenzyme.

24. The colorimetric assay system of claim 5 wherein the oxidase contains a reversible oxidizable dithiol group at its active site.

25. The colorimetric assay system of claim 5 wherein the oxidase contains non-heme iron in its reactive center.

26. The colorimetric assay system of claim 5 wherein the electron transfer agent promotes the transfer of electrons to both the chromogen and the electron acceptor.

27. The colorimetric assay system of claim 5 wherein the reduced chromogen has a millimolar extinction coefficient in excess of 10.

28. The colorimetric assay system of claim 5 wherein the electron acceptor is capable of efficient direct interaction with the enzyme and the electron transfer agent promotes the transfer of electrons to the chromogen.

29. The colorimetric assay system of claim 5 wherein the chromogen is capable of efficient direct interaction with the enzyme and the electron transfer agent promotes the transfer of electrons to the electron acceptor.

30. The colorimetric assay system of claim 5 wherein the electron acceptor, the chromogen, or both the electron acceptor and the chromogen are capable of accepting electrons from the reduced enzyme and from electron transfer agent, wherein the electron transfer agent increases the rate of electron transfer, thereby reducing the amount of enzyme needed to achieve a desired rate.

31. The colorimetric assay system of claim 5 wherein the analyte is glucose, and the enzyme is glucose oxidase.

32. The colorimetric assay system of claim 5 wherein the electron transfer agent and the electron acceptor are a hybrid phenothiazine radical cation, and the chromogen is MTT.

33. The colorimetric assay system of claim 32 wherein the phenothiazine radical cation is prepared from phenothiazine and an electron acceptor oxidizing agent selected from the group consisting of K.sub.2 IrCl.sub.6, NaIO.sub.4, and ferric chelates.

34. The colorimetric assay system of claim 33 wherein the ferric chelate is selected from the group consisting of ferricyanide, ferric EDTA, ferric citrate, ferric oxalate, ferric acetylacetonate, ferric bipyridyl, nitroferricyanide and pentacyanoamino ferrate (III).

35. The colorimetric assay system of claim 5 wherein the assay system is analog to analog and wherein the color change is directly proportional to the concentration of analyte to be measured.

36. The colorimetric assay system of claim 35 wherein the electron acceptor is selected from the group consisting of tartrazine, TFBQ, 2,5,-dihydroxy-1,4-benzoquinone and 2-cyclohexyl-5-hydroxy-1,4-benzoquinone and the chromogen is a tetrazolium salt.

37. The colorimetric assay system of claim 35 wherein the biochemical analyte is bilirubin and the enzyme is bilirubin oxidase.

38. The colorimetric assay system of claim 35 wherein the analyte is cholesterol and the enzyme is cholesterol oxidase.

39. The colorimetric assay system of claim 5, further comprising the the biochemical analyte, the presence or concentration of which is to be measured.

40. The colorimetric assay system of claim 39 wherein the analyte is selected from the group consisting of ethanol, methanol, glucose, lactose, galactose, lactate, pyruvate, oxalate, ketones, albumin, triglycerides, cholesterol, bilirubin, hemoglobin, chlorine, oxalic acid, glycerol, lactic acid, pyruvic acid, ascorbic acid and uric acid, and the enzyme is an oxidase capable of oxidizing the analyte.

41. The colorimetric assay system of claim 5 wherein the oxidase is not capable of oxidizing the analyte as initially present, and wherein the assay system further comprises an enzyme or series of enzymes capable of converting the analyte to a product which can be oxidized by the oxidase.

42. The colorimetric assay system of claim 41 wherein the analyte is triglyceride, the enzyme capable of converting the analyte to a product which can be oxidized by the oxidase is a lipase, and the oxidase is glycerol oxidase.

43. The colorimetric assay system of claim 41 wherein the analyte is esterified cholesterol, the enzyme capable of converting the analyte to a product which can be oxidized by the oxidase is an enzyme with cholesterol esterase activity, and the oxidase is cholesterol oxidase.

44. The colorimetric assay system of claim 5 wherein the color change is a change from a colorless state to a colored stat in the visible range.

45. The colorimetric assay system of claim 5 wherein an additional electron transfer agent is added to promote the efficient transfer of electrons from any reduced chromogen to the electron acceptor.

46. The colorimetric assay system of claim 45 wherein the analyte is in a multi-phase composition and the components of the assay system partition differentially between the phases, and the additional electron transfer agent promotes the flow of electrons from reduced chromogen or electron transfer agent in one phase to the electron acceptor in another phase.

47. The colorimetric assay system of claim 46 wherein the multi-phase composition comprises micellar and ionic aqueous phases.

48. The colorimetric assay system of claim 47 wherein the micellar phase comprises lipoprotein particles and the aqueous phase comprises the aqueous component of blood.

49. The colorimetric assay system of claim 45 wherein the electron acceptor/electron transfer agent is a hybrid.

50. The colorimetric assay system of claim 45 wherein the electron transfer agent is phenazine methosulfate, the electron acceptor is ferricyanide, the chromogen is a tetrazolium salt and the electron transfer agent between the chromogen and the electron acceptor is phenoxazine.

51. A colorimetric assay system which is designed to measure the presence or concentration of an oxidase enzyme in a sample by a color change which is indicative of the presence or concentration of the oxidase, wherein the system comprises,

(a) a substrate which the oxidase is capable of oxidizing by removing electrons from the substrate without involving oxygen in the reaction, wherein the electrons are transferred to an electron acceptor, and wherein the electron acceptor is not oxygen,
(b) a non-chromogenic electron acceptor which is not oxygen, having a half cell reduction potential greater than that of the reduced enzyme, wherein the electron acceptor is capable of accepting electrons from the reduced enzyme in a functionally irreversible manner,
(c) a chromogen which is capable of accepting electrons from the reduced enzyme and changing color in a visible range upon reduction, wherein the change of color is less than one equivalent of color per equivalent of substrate oxidized and is indicative of the presence or the concentration of the oxidase to be determined, and
(d) an electron transfer agent which promotes the transfer of electrons from the reduced enzyme to the electron acceptor, the chromogen, or both the electron acceptor and the chromogen.

52. A diagnostic colorimetric assay device which is designed to measure the concentration of a biochemical analyte in a sample by developing a color signal when the analyte is at or above a threshold concentration and by the absence of a color signal when the concentration of the analyte is below the threshold, wherein the device comprises:

(a) physical support means,
(b) an oxidase enzyme capable of oxidizing the analyte by removing electrons from the analyte without involving oxygen in the reaction, thereby yielding a reduced enzyme,
(c) a non-chromogenic electron acceptor which is oxygen, having a half cell reduction potential greater than that of the reduced enzyme, wherein the electron acceptor is capable of accepting electrons from the reduced enzyme in a functionally irreversible manner,
(d) a chromogen which is capable of accepting electrons from the reduced enzyme and changing color in a visible range upon reduction, wherein the change of color is less than one equivalent of color per equivalent of analyte oxidized and is indicative of the concentration of the analyte to be determined, and
(e) an electron transfer agent which promotes the transfer of electrons from the reduced enzyme to the electron acceptor, the chromogen, or both the electron acceptor and the chromogen.

53. The device of claim 52 wherein the physical support means is a multi-layer dry film or gel situated inside a controlled volume capillary.

54. The device of claim 52 which further comprises a sampling means.

55. The device of claim 54 wherein the sampling means is a lancet for sampling blood.

56. A method for measuring the presence or the concentration of a biochemical analyte in a sample by the development of a color change wherein the method comprises:

(a) contacting the sample with an assay system comprising
(i) an oxidase enzyme capable of oxidizing the analyte by removing electrons from the analyte without involving oxygen in the reaction, thereby yielding a reduced enzyme,
(ii) a non-chromogenic electron acceptor which is oxygen, having a half cell reduction potential greater than that of the reduced enzyme, wherein the electron acceptor is capable of accepting electrons from the reduced enzyme in a functionally irreversible manner,
(iii) a chromogen which is capable of accepting electrons from the reduced enzyme and changing color in a visible range upon reduction, wherein the change of color is less than one equivalent of color per equivalent of analyte oxidized and is indicative of the concentration of the analyte to be determined, and
(iv) an electron transfer agent which promotes the transfer of electrons from the reduced enzyme to the electron acceptor, the chromogen, or both the electron acceptor and the chromogen,
(b) incubating to permit oxidation of the analyte, and
(c) detecting a color change resulting from reduction of the chromogen, wherein a visible color change is indicative of the presence of the analyte or a concentration of the analyte above a predetermined threshold and wherein the absence of a visible color change is indicative of the absence of the analyte or a concentration of the analyte below a predetermined threshold.

57. A method for measuring the presence or the concentration of an oxidase enzyme in a sample by the development of a color change wherein the color change is indicative of the presence or concentration of the oxidase, wherein the method comprises:

(a) contacting the sample with an assay system comprising
(i) a substrate which the oxidase is capable of oxidizing by removing electrons from the substrate without involving oxygen in the reaction, wherein the electrons are transferred to an electron acceptor, and wherein the electron acceptor is not oxygen,
(ii) a non-chromogenic electron acceptor which is not oxygen, having a half cell reduction potential greater than that of the reduced enzyme, wherein the electron acceptor is capable of accepting electrons from the reduced enzyme in a functionally irreversible manner,
(iii) a chromogen which is capable of accepting electrons from the reduced enzyme and changing color in a visible range upon reduction, wherein the change of color is less than one equivalent of color per equivalent of substrate oxidized and is indicative of the concentration of the substrate to be determined, and
(iv) an electron transfer agent which promotes the transfer of electrons from the reduced enzyme to the electron acceptor, the chromogen, or both the electron acceptor and the chromogen,
(b) incubating to permit the oxidation of the substrate, and
(c) detecting a color change resulting from reduction of the chromogen, wherein a visible color change is indicative of the presence of the oxidase or a concentration of the oxidase above a predetermined threshold and wherein the absence of a visible color change is indicative of the absence of the oxidase or a concentration of the oxidase below a predetermined threshold.

58. The colorimetric assay system of claim 39, further comprising a reactant which reacts with the analyte to convert the analyte to a product in situ, and an oxidase capable of oxidizing the product.

59. The colorimetric assay system of claim 49 wherein the electron acceptor/electron transfer agent hybrid is phenothiazine radical cation, the electron transfer agent between the enzyme and the chromogen is DMMBQ, and the electron transfer agent between the chromogen and the electron acceptor is TFBQ.

60. A colorimetric assay system which is designed to measure the presence or concentration of a biochemical analyte in a sample by a color change which is determinative of the presence or concentration of the analyte, which system comprises:

(a) a heme- or copper-containing protein capable of oxidizing the analyte by removing electrons from the analyte without involving oxygen in the reaction thereby yielding a reduced protein,
(b) a chromogen which is capable of accepting electrons from the reduced protein and is capable of changing color in a visible range upon reduction, the change of the reduced chromogen being detectable and determinative of the presence or concentration of the analyte to be determined, and
(c) a non-chromogenic electron acceptor which is not oxygen, having a half cell potential greater than the reduced enzyme, wherein the electron acceptor is capable of accepting electrons from the reduced enzyme in a functionally irreversible manner, and
(d) an electron transfer agent which promotes the transfer of electrons from the reduced enzyme to the electron acceptor, the chromogen, or both.

61. The colorimetric assay system of claim 60, wherein the heme- or copper-containing protein is selected from the group consisting of serum monoamine oxidase, liver dopamine hydroxylase, hemocyanin, laccase, uricase, phenolase, transsulferase, cerebrocuprein, erythrocyprein, hepatocuprein, plastocyanin, dopamine-2-hydroxylase, liver aryl-4-hydroxylase, liver naphthalene hydroxylase, alkoxyaryl hydroxylase and fatty acid desaturase.

Drawings